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**Abstract**

The prevalence of cannabis dependence (CaD) is increasing in the United States, where action to legalize use of the substance is worsening an existing public health problem.

Although genetic factors contribute substantially to CaD risk, there are at present no well-established specific genetic risk factors for CaD. Over a 15-year period, we collected a sample of \>10,000 subjects, ascertained for opioid, cocaine, or alcohol dependence, or because they were controls; and completed a series of genomewide association studies (GWAS) for these substance dependence traits, as well as nicotine dependence. In light of its biological and medical interest and because cannabis use and dependence are prevalent in our sample, we performed a GWAS for DSM-IV cannabis dependence criterion count. We also included in our GWAS publicly-available data, e.g. from the SAGE consortium. This resulted in a subject sample including 6,063 African-American and 8,866 European-American subjects, including some small families. We identified three distinct regions with genome-wide significant SNP associations with variants mapped to genes encoding antisense transcript *RP11-206M11.7*; solute carrier family 35, member G1 (*SLC35G1*); and cub and sushi multiple domains 1 (*CSMD1*). We also found evidence for genome-level pleiotropy between CaD and major depressive disorder, and for association with SNPs in genes associated with schizophrenia risk. Several of the genes implicated have functions related to neuronal calcium homeostasis or central nervous system development.

This is, to our knowledge, the first study to identify specific CaD risk alleles and identify potential genetic factors contributing to the co-morbidity of CaD with major depression and schizophrenia.
